Form 4: Clene Inc. Director Jonathon Gay Acquires Stock Options

Director Jonathon Gay acquired stock options for 30,000 shares of Clene Inc. common stock on May 29, 2024.

Summary

• On May 29, 2024, Jonathon Gay, a director of Clene Inc., was granted stock options to purchase 30,000 shares of the company's common stock.
• The exercise price for these options is $0.37 per share.
• The options vest in 12 equal monthly installments starting June 29, 2024, and expire on May 28, 2034.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. The grant itself can be seen as a positive sign of aligning director interests with shareholders, but it's not a major event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 12 months is fairly typical, encouraging continued service and alignment with long-term company performance.
• Comparing the exercise price and the number of options granted to similar companies and director roles would provide a more comprehensive assessment of the grant's value and competitiveness.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
• The grant has a dilutive effect on existing shareholders, although the impact is likely minimal given the size of the grant.

Key Dates